PerkinElmer, Inc., have intoriduced the new EUROIMMUN Aspergillus Antigen ELISA* which is specifically designed to detect the Aspergillus antigen galactomannoprotein and assist in distinguishing invasive aspergillosis (IA).

“Timely detection and diagnosis of this dangerous infection is critical to ensuring proper treatment and preventing fatalities,” said Dr. Wolfgang Schlumberger, Ph.D., CEO of EUROIMMUN, a PerkinElmer company. “Clinical studies have shown that the EUROIMMUN Aspergillus Antigen ELISA delivers high sensitivity and specificity in detecting galactomannoprotein. And, when processed using the automated EUROIMMUN Analyzer system, our ELISA seamlessly integrates into a laboratory workflow for faster detection of Aspergillus infections at an earlier stage.”

Detection of Aspergillus antigen is included in the guidelines of the Infectious Diseases Society of America (IDSA), the European Organization for Research and Treatment of Cancer (EORTC) and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (MSG) as a criterion of a “probable” IA infection.

 

For more information about the EUROIMMUN Aspergillus Antigen ELISA, visit www.euroimmun.com

 

*PerkinElmer’s EUROIMMUN Aspergillus Antigen ELISA is available for research use only and not for use in diagnostics in the United States. Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.